Complete Filing Data
MBX Biosciences, Inc. reported Stockholders Equity of $369.22 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean MBX Biosciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$87.0M | -$61.9M | -$32.6M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $231.0K | -$5.0K | $57.0K |
| Research And Development Expense | $79.2M | $57.4M | $28.5M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $285.0K | $54.0K | $60.0K |
| Operating Income Loss | -$98.1M | -$68.2M | -$35.3M |
| Operating Expenses | $98.1M | $68.2M | $35.3M |
| Net Income Loss Available To Common Stockholders Basic | -$87.0M | -$61.9M | -$32.6M |
| General And Administrative Expense | $18.9M | $10.8M | $6.8M |
| Comprehensive Income Net Of Tax | -$86.7M | -$61.9M | -$32.5M |
| Other Comprehensive Income Loss Reclassification Adjustment From AOCI For Sale Of Securities Net Of Tax | $54.0K | $59.0K | $3.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$21.6M | -$19.4M | -$23.9M | -$18.1M | -$15.9M | -$12.3M | -$10.2M | -$7.6M | -$5.9M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $143.0K | -$42.0K | -$2.0K | $121.0K | -$12.0K | -$63.0K | $9.0K | -$4.0K | $1.0K |
| Research And Development Expense | $19.3M | $17.7M | $22.4M | $16.7M | $14.4M | $11.0M | $9.1M | ||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $143.0K | -$42.0K | -$2.0K | $121.0K | -$12.0K | -$63.0K | $9.0K | ||
| Operating Income Loss | -$23.9M | -$21.8M | -$26.5M | -$19.6M | -$16.7M | -$13.3M | -$10.9M | ||
| Operating Expenses | $23.9M | $21.8M | $26.5M | $19.6M | $16.7M | $13.3M | $10.9M | ||
| Net Income Loss Available To Common Stockholders Basic | -$21.6M | -$19.4M | -$23.9M | -$18.1M | -$15.9M | -$12.3M | -$10.2M | ||
| General And Administrative Expense | $4.7M | $4.1M | $4.1M | $2.9M | $2.3M | $2.3M | $1.9M | ||
| Comprehensive Income Net Of Tax | -$21.5M | -$19.5M | -$23.9M | -$18.0M | -$15.9M | -$12.4M | -$10.2M | ||
| Other Comprehensive Income Loss Reclassification Adjustment From AOCI For Sale Of Securities Net Of Tax |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $369.2M | $257.4M | -$72.5M | -$42.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $75.3M | $49.4M | $30.5M | $24.2M |
| Share Repurchase Liability | $2.0K | $42.0K | $194.0K | |
| Retained Earnings Accumulated Deficit | -$224.5M | -$137.5M | -$75.6M | |
| Property Plant And Equipment Net | $2.7M | $1.1M | $439.0K | |
| Prepaid Expense And Other Assets Current | $7.8M | $5.1M | $2.8M | |
| Other Assets Noncurrent | $383.0K | $50.0K | $50.0K | |
| Operating Lease Right Of Use Asset | $487.0K | $119.0K | $226.0K | |
| Operating Lease Liability Current | $172.0K | $171.0K | $153.0K | |
| Non Cash Operating Lease Expense | $133.0K | $106.0K | $95.0K | |
| Marketable Securities Current | $298.4M | $212.8M | $50.2M | |
| Liabilities Current | $15.5M | $11.1M | $3.9M | |
| Liabilities And Stockholders Equity | $385.1M | $268.5M | $84.2M | |
| Liabilities | $15.9M | $11.1M | $4.3M | |
| Common Stock Value | $6.0K | $5.0K | $1.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $25.9M | $18.8M | $6.3M | |
| Cash And Cash Equivalents At Carrying Value | $75.3M | $49.4M | $30.5M | |
| Assets Current | $381.5M | $267.3M | $83.5M | |
| Assets | $385.1M | $268.5M | $84.2M | |
| Additional Paid In Capital Common Stock | $593.4M | $394.9M | $3.1M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $286.0K | $55.0K | $60.0K | |
| Accrued Liabilities Current | $12.3M | $5.5M | $2.4M | |
| Accretion Amortization Of Discounts And Premiums Investments | $3.6M | $2.9M | $1.0M | |
| Accounts Payable Current | $3.0M | $5.3M | $1.4M | |
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | |
| Operating Lease Liability Noncurrent | $424.0K | $0.00 | $171.0K | |
| Payment Of Preferred Stock Issuance Costs | $0.00 | $279.0K | $30.0K | |
| Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses | $127.0K | $0.00 | ||
| Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering | $0.00 | $215.6M | ||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | $0.00 | $152.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $387.5M | $219.2M | $235.4M | $271.4M | -$97.9M | -$83.0M | -$64.8M | -$55.4M | -$48.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $223.1M | $39.8M | $29.9M | $132.9M | $12.5M | $35.4M | $70.6M | ||
| Share Repurchase Liability | $7.0K | $15.0K | $23.0K | $68.0K | |||||
| Retained Earnings Accumulated Deficit | -$202.4M | -$180.8M | -$161.4M | -$121.9M | |||||
| Property Plant And Equipment Net | $2.0M | $1.7M | $1.5M | $1.0M | |||||
| Prepaid Expense And Other Assets Current | $5.8M | $4.3M | $3.5M | $4.1M | |||||
| Other Assets Noncurrent | $50.0K | $50.0K | $50.0K | $50.0K | |||||
| Operating Lease Right Of Use Asset | $520.0K | $551.0K | $91.0K | $147.0K | |||||
| Operating Lease Liability Current | $154.0K | $138.0K | $130.0K | $166.0K | |||||
| Non Cash Operating Lease Expense | $29.0K | $25.0K | |||||||
| Marketable Securities Current | $168.5M | $185.1M | $210.9M | $144.2M | |||||
| Liabilities Current | $12.1M | $11.8M | $10.5M | $10.9M | |||||
| Liabilities And Stockholders Equity | $400.1M | $231.5M | $245.9M | $282.4M | |||||
| Liabilities | $12.5M | $12.3M | $10.5M | $11.0M | |||||
| Common Stock Value | $6.0K | $5.0K | $5.0K | $5.0K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$19.4M | $4.9M | |||||||
| Cash And Cash Equivalents At Carrying Value | $223.1M | $39.8M | $29.9M | $132.9M | |||||
| Assets Current | $397.5M | $229.2M | $244.3M | $281.2M | |||||
| Assets | $400.1M | $231.5M | $245.9M | $282.4M | |||||
| Additional Paid In Capital Common Stock | $589.8M | $400.0M | $396.7M | $393.2M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $154.0K | $11.0K | $53.0K | $106.0K | |||||
| Accrued Liabilities Current | $8.1M | $5.9M | $6.1M | $5.8M | |||||
| Accretion Amortization Of Discounts And Premiums Investments | $1.3M | $503.0K | |||||||
| Accounts Payable Current | $3.8M | $5.8M | $4.2M | $5.0M | |||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | ||||||
| Operating Lease Liability Noncurrent | $469.0K | $512.0K | $44.0K | ||||||
| Payment Of Preferred Stock Issuance Costs | |||||||||
| Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses | $0.00 | $1.7M | |||||||
| Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering | |||||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $8.7M | $5.2M | $2.0M |
| Proceeds From Stock Options Exercised | $2.4M | $403.0K | $739.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $267.9M | $79.8M | $33.0M |
| Payments To Acquire Property Plant And Equipment | $1.9M | $874.0K | $129.0K |
| Payments To Acquire Marketable Securities | $358.1M | $239.5M | $63.8M |
| Net Cash Provided By Used In Operating Activities | -$79.9M | -$54.7M | -$32.0M |
| Net Cash Provided By Used In Investing Activities | -$83.7M | -$160.6M | -$30.9M |
| Net Cash Provided By Used In Financing Activities | $189.6M | $234.1M | $69.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.7M | $2.3M | $1.0M |
| Increase Decrease In Operating Lease Liability | $425.0K | -$153.0K | -$137.0K |
| Increase Decrease In Accrued Liabilities | $6.8M | $3.2M | $45.0K |
| Increase Decrease In Accounts Payable | -$2.5M | $3.9M | $412.0K |
| Payments Of Stock Issuance Costs | $771.0K | $4.1M | |
| Proceeds From Call Redemptions Of Marketable Securities | $8.5M | $0.00 | |
| Proceeds From Issuance Initial Public Offering | $0.00 | $174.5M | |
| Increase Decrease In Operating Lease Right Of Use Asset | $501.0K | $0.00 | |
| Proceeds From Issuance Public Offering | $187.9M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $1.8M | $1.6M |
| Proceeds From Stock Options Exercised | $4.0K | $189.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $57.2M | $24.3M |
| Payments To Acquire Property Plant And Equipment | $30.0K | $273.0K |
| Payments To Acquire Marketable Securities | $58.9M | $8.5M |
| Net Cash Provided By Used In Operating Activities | -$22.7M | -$10.7M |
| Net Cash Provided By Used In Investing Activities | $3.2M | $15.4M |
| Net Cash Provided By Used In Financing Activities | $4.0K | $183.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.6M | -$408.0K |
| Increase Decrease In Operating Lease Liability | -$42.0K | -$37.0K |
| Increase Decrease In Accrued Liabilities | $558.0K | -$411.0K |
| Increase Decrease In Accounts Payable | -$1.6M | $474.0K |
| Payments Of Stock Issuance Costs | $0.00 | $6.0K |
| Proceeds From Call Redemptions Of Marketable Securities | $5.0M | $0.00 |
| Proceeds From Issuance Initial Public Offering | ||
| Increase Decrease In Operating Lease Right Of Use Asset | ||
| Proceeds From Issuance Public Offering |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 36.5M | 10.6M | 1.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 36.5M | 10.6M | 1.0M |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Earnings Per Share Diluted | $-2.38 | $-5.82 | $-31.96 |
| Earnings Per Share Basic | $-2.38 | $-5.82 | $-31.96 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 237.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 |
| Common Stock Shares Outstanding | 44.9M | 33.4M | 1.3M |
| Common Stock Shares Issued | 44.9M | 33.4M | 1.3M |
| Temporary Equity Shares Outstanding | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 34.2M | 33.4M | 33.4M | 6.5M | 1.3M | 1.2M | 1.1M |
| Weighted Average Number Of Diluted Shares Outstanding | 34.2M | 33.4M | 33.4M | 6.5M | 1.3M | 1.2M | 1.1M |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Earnings Per Share Diluted | $-0.63 | $-0.58 | $-0.71 | $-2.78 | $-12.62 | $-10.26 | $-9.40 |
| Earnings Per Share Basic | $-0.63 | $-0.58 | $-0.71 | $-2.78 | $-12.62 | $-10.26 | $-9.40 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Common Stock Shares Outstanding | 44.7M | 33.6M | 33.4M | 33.4M | |||
| Common Stock Shares Issued | 44.7M | 33.6M | 33.4M | 33.4M | |||
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $2.4M | $568.0K | $600.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $8.7M | $5.2M | $2.0M |
| Interest And Other Income | $11.1M | $6.3M | $2.7M |
| Depreciation | $248.0K | $244.0K | $157.0K |
| Capital Expenditures Incurred But Not Yet Paid | $26.0K | $29.0K | $18.0K |
| Stock Issued During Period Shares Stock Options Exercised | 398.5K | 108.7K | 250.3K |
| Vesting Of Early Exercised Stock Options And Founder Shares | 40.0K | 232.0K | 504.0K |
| Vesting Of Early Exercised Stock Options | |||
| Stock Repurchased During Period Value | $19.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $139.0K | $1.3M | $4.0K | $35.0K | $112.0K | $198.0K | $129.0K | $269.0K | $77.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.2M | $1.9M | $1.8M | $1.2M | $919.0K | $1.6M | $595.0K | $225.0K | $204.0K |
| Interest And Other Income | $2.3M | $2.4M | $2.6M | $1.5M | $801.0K | $977.0K | $783.0K | ||
| Depreciation | $100.0K | $100.0K | $77.0K | $100.0K | $100.0K | $48.0K | $100.0K | ||
| Capital Expenditures Incurred But Not Yet Paid | $502.0K | $34.0K | |||||||
| Stock Issued During Period Shares Stock Options Exercised | 3.0K | ||||||||
| Vesting Of Early Exercised Stock Options And Founder Shares | |||||||||
| Vesting Of Early Exercised Stock Options | $19.0K | $114.0K | |||||||
| Stock Repurchased During Period Value | $19.0K |
Most recent annual filing with the SEC: March 12, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.